Skip to main content
Journal of Foot and Ankle Research logoLink to Journal of Foot and Ankle Research
. 2025 Jul 24;18(3):e70062. doi: 10.1002/jfa2.70062

Bibliometric Analysis: Insights Into the Podiatric Medicine Landscape of Diabetic Sensory Peripheral Neuropathy and Genomics

Benjamin M Jones 1,, Reuben J Pengelly 2, Alan M Borthwick 1, Catherine J Bowen 1
PMCID: PMC12289441  PMID: 40708097

Abstract

Background and Aims

Research into diabetic foot complications is extensive; it remains challenging to identify critical literature. Evolving interprofessional boundaries, alongside advances in molecular medicine and pathophysiological understanding, necessitates mapping of the scientific literature (corpus). Impact of these advances on podiatric medicine remains unclear. This study explores topics, research performance, and evolution across the literature and disciplines to understand the corpus in its current state.

Method

A retrospective‐observational bibliometric analysis examined Web of Science publications using PRISMA search strategy (August 2023) to understand interconnectedness, direction, and intersectionality of subject disciplines, growth areas, and output. Curated phrases and disease focussed classification anchored investigation to diabetic peripheral neuropathy. Qualitative and quantitative approaches analysed publication meta‐data (authors, citations, keywords) to map key concepts and scientific developments.

Results

Analysis of 589 records (1991–2023) revealed observational studies as the dominant design. Prominent concepts included risk, polyneuropathy, and prevalence, with authors favouring accessible terms (peripheral neuropathy) across specialisms. Leading research hubs were in England, Demark, USA, Qatar, Germany, and Italy. Diabetic Medicine and Diabetes Care remained the highest‐cited journals, whilst the International Journal of Molecular Science, Cell Stem Cell, and Nature Reviews Neurology provided contemporary insights. Post‐2016, methodological rigour and objectivity increased.

Discussion

Recurring topics included enhancing pre‐clinical screening, addressing earlier diagnosis, pain management stratification with medicines optimisation, and reproducibility challenges. Case‐controls increasingly replaced larger prospective, longitudinal study designs to improve diagnostic test accuracy and detection of diabetic neuropathy, particularly for neuropathic pain affecting small nerve fibres. Molecular approaches gained prominence signalling a shift from purely clinically derived approaches. The corpus responded to subjectivity and variable diagnostic criteria by prioritising objectivity. Emerging insights into channelopathies and mitochondrial dysfunction may augment current assessment/screening approaches to refine risk stratification and management strategies.

Keywords: bibliometric, diabetes, genomics, peripheral neuropathy, podiatry

1. Introduction

Diabetic foot disease (DFD) is estimated to contribute 1.8% towards total global disease burden when using disability‐adjusted life‐years [1]. Peripheral neuropathy (PN), without ulceration or amputation, represents the largest proportion of DFD and receives limited attention [1]. International guidelines rely upon broad definitions for PN usually referring to nonspecific dysfunction, despite representing a core subpopulation that can receive preventative approaches if intervention is sufficiently early [2, 3]. This lack of detail to form or subtyping, for example, sensory over motor, constrains guideline value [4]; not all forms of peripheral neuropathy are equal. Guidelines do not reflect compelling evidence that characterisation of PN is necessary to improve diagnostics and prognostic approaches [5, 6, 7, 8, 9, 10]. The IWGDF 2023 risk stratification for ‘at‐risk of foot ulceration’ provides risk categorisation of 1 (low) when loss of protective sensation is identified reflecting progress towards differentiation of 0 (very low risk) [11, 12]. However, the spectrum between fully sensate and dysfunctional retains a ‘present or absent’ approach. Investigation into the scientific literature of diabetic foot complications (DFC) is needed to highlight topics, gaps and evolution to understand how approaches have integrated fields and expertise.

Previous bibliometric analysis in the field of DFD covered 1955–2023 with a variety of professional lenses [13, 14, 15, 16, 17, 18]. Diabetic limb salvage groups identified extensive volume and breadth for practitioners to traverse in updating the practice in 2012 analysis [18]. The sheer volume renders comprehensive reading impossible across the scientific corpus (the total body of scientific research dedicated to the subject matter); breadth of fields makes identification across disciplines difficult when appraising where to target first. Surgical management teams 1992–2010 identified intellectual structures on tissue integrity, restoration and management. Core themes, surgical‐management and diabetic journey‐related emerged from n = 1229 articles to n = 122 reviews; however, the research did not reflect the expanse of fields involved across the life course of patients living with diabetes (PLWD) [17]. Prevention and prediction have been slow to emerge in the corpus despite urgency to reduce DFC incidence; early action to prevent poor health outcomes (AR1 [area of research interest objective]) is a critical research priority for Department of Health and Social Care, UK [19]. Language and focus from surgical to multidisciplinary across these periods marked the transition from reactive to proactive approaches; migrating away from ‘diabetic foot’ ∼1955 to ‘diabetes‐related foot disease’ ∼2020, showing an evolving lexicon (language) seeking precision [13, 16].

Journals, ‘Diabetes Care’, ‘Diabetic Medicine’ and ‘Diabetologia’, have historically housed most DFC research [20]. Understanding where new research is emerging can highlight new structures within the corpus—USA, England, Germany and Italy have consistently been identified as high‐produces [17] alongside increasing output from China, Australia and the Netherlands [15]. The type of research produced globally can locate the contemporary nexuses of talent. Researchers and clinicians alike can draw on this expertise in a targeted fashion. To illustrate, an Australian‐only bibliometric analysis [14] (n = 322 articles; drawn only from Scopus) between 2012 and 2021 noted a five‐fold increase in their annual publication alone. Their evaluation of research types, using UKCRC Health Research Classification System, indicated progress with aetiology and treatment evaluation. Screening and diagnosis research remained low and prevention was virtually nonexistent [14]; the paucity may be a global phenomenon and not isolated to Australia. However, knowledge deficits inevitably necessitate clinicians and researchers to source from international research that may not transfer as readily to their local setting or population.

Finally, genetic research on diabetic foot ulcers (DFU) has seen an increased representation in lower limb‐centric journals (2007–2021) [21, 22]. DNA variation impacting DFU can include multiple body systems, for example, inflammatory‐centric, vascular and neurological, reflecting a wide range of research areas to digest [21, 23, 24]. Genetic risk scoring, for example, has been investigated in prevention to support assessment for type 2 diabetic patients through identification of genetic high‐risk susceptibility [25]. However, robust clinical translation has been mixed overall [26, 27, 28, 29], thus inviting discussion on how applications would impact DFC. Utilising one prominent DFC (that can yield preventative and prognostic potential), this study sought to understand where the research focus was occurring, the form and direction alongside evolution. Using a collection of research constituents (authors, institutions, countries) across the literature and disciplines, we employed a variety of bibliometric output metrics to assist in deriving topics and mapping knowledge domains to understand intellectual structures (prominent areas of focus) (Glossary of terms available in Supporting Information S1).

2. Materials and Method

Best practice guidelines were adhered to using PRIBA reporting [30]. To understand knowledge structures (conceptual, intellectual and social), use of performance and network analysis were mapped to meet the study's aims and objective. The underlying constituents were sourced from articles and reviews to analyse authors, keywords, citations, journals, institutions and countries (See Supporting Information S2 for source and metric).

2.1. Metric Selection

Performance metrics using total frequency, frequency per year, or averages across citations of papers, authors, keywords, keywords plus, or other relevant research constituents were chosen to identify highest performing elements (Further details Supporting Information S3). Summary of component mapping‐to‐objectives are found in Supporting Information S2: Table S1. Recommendations by Donthu et al. 2021 [31] were followed to ensure maximisation of breadth of techniques for analysis were employed.

2.2. Search Strategy

Exploration focused upon ‘no‐ or low‐risk’, as defined by NG19 (NICE Guidelines) [32], diabetic sensory peripheral neuropathy (DSPN) and corresponding neurological assessments with overlapping genomics. A curated selection, n = 15 papers (Supporting Information S4: Table S2), was used to define optimal keywords (see Table 1). The focus centred upon a key trait: Peripheral neuropathy within the diabetic population, across podiatry and genomics; search was restricted to include diabetic foot complications/ulcers to ensure anatomical preference in the lower limb. Common assessments or emerging modalities were used to help encapsulate risk/categorisation (See Supporting Information S4 Search Strategy Expanded for full breakdown). The approach sought a balance between stringency and inclusivity, achieving an initial dataset (n = 1277) (Figure 1). This approach overlapped with assessments for DFC, therefore formed the necessary boundaries of search, which included all forms of articles until final search on 31st August 2023.

TABLE 1.

Included keywords/phrases selected with justifications: These shaped the bibliometric search for papers accounting for synonyms.

Keywords/phrases Justification
Diabet* AND Peripheral Neuropath* OR Polyneuropath*

Podiatric centric implications

Capture target population

Early literature (established high‐ranking words)

Capture target physiological measure

Sensory OR Diffuse OR Sensorimotor OR Distal OR symmetrical OR vibration

Capture target population

Early literature (established high‐ranking words)

Capture target physiological measure

Assessment OR Categorisation OR Categorization OR vibration OR quantitative testing

Broader literature (established high‐ranking words)

Contemporary literature and preferred target

Capture modalities use to evaluate peripheral neuropathy

Reveal current topic in intellectual structures

Delineate current state of prognostication

Genom* OR Gene* Or Polymorphism OR SNP OR Mutation* OR phenotyp*

Peripheral Neuropath* (PN)

Genetic/genomic focus

Developing literature (high‐ranking wording)

Modern literature (accurate wording selection)

Reveal current topic in intellectual structures

Risk OR Risk Profile OR Stratification OR Prognosis OR Prognostication OR personalised medicine

Modern literature (accurate wording selection)

Delineate risk as an intellectual constituent

Capture modalities use to evaluate peripheral neuropathy

Reveal current ranking to risk categories

Delineate current state of prognostication

Note: During analysis, phrases were critical when applying filters to understand and ensure capture of nuanced insight.

FIGURE 1.

FIGURE 1

PRISMA workflow.

2.3. Study Selection

Single author [B.J.] screening utilised the Rayyan.AI software [33]. The screening author's previous clinical career was as a specialist podiatrist, thus able to draw upon clinical insights and application to verify relevancy of material to practice [34]. Inclusion criteria remained broad to capture assessments, basic science and genetic features (mutations or polymorphisms) alongside key phenotype of sensory neuropathy (regardless of form). Breadth of document type was desirable in discerning where research was located, for example, primary articles and reviews. Therefore, we included editorials, books, proceedings and abstracts, for example, conferences, short reports and reviews. Exclusion of case studies, case series and animal‐models occurred. Treatment‐centric publications within the inclusion criteria that conducted clinical neuropathic assessments using either quantitative sensory testing or perception thresholds were permissible where abstracts indicated relevancy. Exclusion further removed intervention‐only studies and drug induced peripheral neuropathy, for example, chemotherapy‐induced, as the cause of DSPN. Sources reporting off‐target but overlapping subjects, for example, Fabry and Gaucher Rare Diseases, or where nonhuman samples was reported, were also excluded.

The terms excluded or merged to improve analysis, for example, Fibre and Fibre, to provide accurate count during analysis are supplied within Supporting Information S11. The exclusion terms file removed core words/phrases where, as primary search terms as they would have been overrepresented (therefore trivial) (Supporting Information S6: Figures SF7–SF12 demonstrate the impact of filters upon results). This improved accessibility of emerging terms that had smaller representation, thus indicating new or hidden concepts as they entered top 10–30 (see Supporting Information S4: Tables ST4 and ST5). Filters were applied selectively during analysis only (appropriately delineated within relevant results section).

2.4. Data Preprocessing and Quality Control

We assessed for completeness of data and determined dataset to be robust (See Supporting Information S10; Figure S2).

2.4.1. Database Selection

The Web of Science (WoS) repository was accessed: 31st August 2023. This database offered adequate biomedical coverage and provided optimal compatibility when intergrated with selected analytical software returing the most robust dataset. Cochrane, Len.org, Embase and Scopus databases were excluded as exported records lacked adequate quality to conduct analysis.

2.4.2. Software

Screening: Rayyan.AI [33] software as a service (SaaS) Webform: Accessed on 25th August 2023. No version number available at time of use.

Analysis: Biblioshiny was the principle platform for analysis (Bibliometrix version 4.1.4, which integrated BIBLIOMETRIX [35] GEPHI [36] VOSviewer [37]).

2.5. Data Analysis

All findings were returned to the team [R.P., C.B., and A.B.] for discussion and interpretation. Performance metrics, for example, highest output, were reported to provide snapshot/summary over time and raise awareness of authors, subject matter expertise, and prominent papers to guide this analysis and discussion only. Descriptive analysis of performance (contribution), as noted in Donthu et al. (2021) [31], was selected to elucidate which authors held sway through metrics to identify core contributors that shaped the corpus and direction. Core sources (journals) were investigated to determine where publications resided to give sense to structure, further supported by employing ‘Bradford's Law’ to visualise their presence. Co‐occurrence and co‐citation provided insight to relationships between constituents and were explored analytically. The m‐index was selected for journals and authors to help identify contemporary value. This metric takes the Hirsch index (h‐index) and divides this by the number of years since the author’s first publication. A h‐index, briefly, measures how many authors publications have been cited as least as many time. The m‐index constrains time to help interpret the balance between publications, citations, and recency. It is intended to highlight contemporaneousness of authorship and improve comparrison against well‐established authors.

3. Results

3.1. Overview

The eligible dataset covered 1991–2023, with sample of n = 589 records containing n = 246 sources; articles were most prominent n = 424 (72%) followed by reviews n = 119 (20%). The breakdown of record characteristic can be found in Table 2. Exploring averages across document types, growth rate was 2.19% annually, document age ∼12 years and citations per document were 51.64 across n = 17,573 references. Total of n = 1414 ‘Keyword Plus’ terms were identified and n = 2550 authors. Of which, n = 38 (0.015%) were single‐authored documents. Co‐authorship per document was n = 6.14 and international co‐authorship reflected 25.47% of sample. Peak research article production occurred in 2021 with n = 44 (range 22–44) climbing gradually from 1993. The citation average per year peaked in 1993 with 12.5 (range 1–12.5) and from 1995 to 2021, the range of the citation average remained within 2–6 per year (Data were not shown for peaks and citation average year).

TABLE 2.

Record characteristics and overview of records.

Description Results
Main information about data
Timespan 1991:2023
Sources (journals, books, etc.,) 246
Documents 589
Annual growth rate % 2.19
Document average age 12
Average citations per doc 51.64
References 17,573
Document contents
Keywords plus (ID) 1414
Author's keywords (DE) 1022
Authors
Authors 2550
Authors of single‐authored documents 38
Authors collaboration
Single‐authored documents 45
Co‐authors per document 6.14
International co‐authorships % 25.47
Document types
Article 424
Article; book chapter 7
Article; early access 4
Article; proceedings paper 19
Editorial material 2
Meeting abstract 8
Note 1
Proceedings paper 3
Review 119
Review; book chapter 1
Review; early access 1

A deeper exploration of highly cited and influential studies (n = 37) revealed that observational investigations were the most frequent approach. Subgroup characteristics consisted of: Cross‐sectional studies (13) [6, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48], cohort (9) [6, 38, 49, 50, 51, 52, 53, 54, 55], reviews (9) [8, 10, 56, 57, 58, 59, 60, 61, 62], epidemiology (6) [6, 38, 55, 56, 63, 64], case–control (3) [65, 66, 67], position statements (2) [68, 69], validation/other (2) [7, 9], guidelines (1) [70] and special reports (1) [71]. Classification of studies reflects the updated precision in study design and evidence‐based medicine [72, 73, 74, 75, 76, 77, 78, 79, 80]. A collation of common instruments, trials and guidance can be found in Table 3.

TABLE 3.

Collation of instruments, major studies and consensus guides prevalent with the articles.

Instruments Trials/major survey/national dataset

Michigan Neuropathy Screening Instrument (MNSI)

Michigan Neuropathy Screening Instrument Examination part (MNSI‐E)

Michigan Diabetic Neuropathy Score (MDNS)

Neuropathy Diabetes Score [1980] [81]

Neuropathic Disability Score

Neuropathy Symptom Score

Neuropathy Symptom Score [Modified]

Neuropathy Symptom Profile [1986] [82]

Total Neuropathy Score

Neuropathy Total Neuropathy Score‐6

Toronto Clinical Scoring System

Toronto Neuropathic Clinical Score (TNCS)

Modified‐Toronto Neuropathic Clinical Score (TNCS)

Utah Early Neuropathy Scale

LANSS (Leeds Assessment of Neuropathic Symptoms and Signs)

Overall Neuropathy Limitation Scale (ONLS)

PainDETECT

Douleur Neuropathique en 4 Questions (DN4)

Neuropathic Pain Symptom Inventory (NPSI)

Brief Pain Inventory (BPI)

Seattle Prospective Diabetic Foot Study

Rochester Diabetic Neuropathy Study

UK Prevalence Study 1993

EURODIAB IDDM Complications Study

National Health and Nutrition Examination Survey

Pain in Neuropathy Study (PiNS)

German Diabetes Study Group

Methods for early detection of diabetic peripheral neuropathy (MEDON)

Danish National Patient Register

UK Bioresource Rare Disease Project

UK Primary Care CPRD Gold Database

Consensus guides (for diagnosis)

San Antonio Consensus Criteria

Mayo Clinic Classification

Revised American Diabetes Association Recommendation

3.2. Language, Subject Categories and Core Concepts

Keyword plus across 1991–2023 delineated the core concepts (See Table 4); higher frequency indicated strength within the corpus. Application of the synonym filter revealed risk (129) was greater in importance than polyneuropathy (104). Exclusion terms (alongside synonym filter) re‐ranked accordingly: Prevalence (99), complications (64), foot ulceration (51), diagnosis (48) and skin biopsy (38) (Supporting Information S4: Figure S3). Focus centred upon clinical presentation, umbrella terms and impact (See Supporting Information S4: Keyword Plus and Author Keywords). Subject categories (WoS) revealed clinical neurology and neuroscience contained the most relevant research followed by medicine general and internal, biochemistry and molecular biology, and anaesthesiology (Supporting Information S4: Figure S4).

TABLE 4.

Top‐10 keyword plus and author keywords presented without filters applied to demonstrate “as is” state of the corpus.

Top‐10 keyword plus Top‐10 author keywords
Peripheral neuropathy (184) Diabetic neuropathy (84)
Polyneuropathy (103) Neuropathy (79)
Prevalence (99) Diabetes mellitus (58)
Risk‐factors (82) Peripheral neuropathy (52)
Mellitus (73) Diabetes (51)
Sensory neuropathy (67) Quantitative sensory testing (49)
Complications (64) Diabetic peripheral neuropathy (37)
Foot ulceration (51) Skin biopsy (31)
Diagnosis (48) Neuropathic pain (29)
Corneal confocal microscopy (44) Small fibre neuropathy (29)

Author keywords presented a different focus (Table 4). These revealed modalities of quantitative sensory testing and skin biopsy were more prominent concepts pertaining to peripheral neurological assessment. Synonym filter consolidated concepts to rerank accordingly: Peripheral neuropathy (104), quantitative sensory testing (51), small fibre neuropathy (44) and painful neuropathy (38). Additional exclusion filter saw hidden concepts, diabetic foot (24), nerve conduction studies (16) and diagnosis (15) elevate in prominence. Authors centred on practical applications and approaches.

3.2.1. Co‐Occurrence

Centrality metrics quantitatively demonstrate where connections convey information effectively (in volume, across fields and journals). High betweenness measures propagation of shared meaning. Prevalence, as a concept, is universally understood, indicating the corpus is aware of the health burden resulting from peripheral neuropathy alongside other complications, particularly DFU. Low centrality measures in primary health care and health care sciences and services revealed these intellectual structures underperformed comparative to high conveyers: Clinical neurology and neuroscience (See Table 5).

TABLE 5.

Noteworthy centrality measures in keyword plus and subject categories.

Centrality measure Centrality
Keywords plus (unfiltered top 5)
Peripheral neuropathy 290.39
Polyneuropathy 75.20
Prevalence 55.04
Sensory neuropathy 50.04
Risk‐factors 39.04
Keywords plus (filtered top 5)
Prevalence 323.52
Foot ulceration 62.25
Impaired glucose‐tolerance 50.18
Complications 49.82
Skin biopsy 47.90
Subject categories (top 3; filter not applicable)
Clinical neurology 124.77
Neurosciences 122.22
Biochemistry and molecular biology 112.01
Subject categories (low 3; filter not applicable)
Primary health care 3.64
Genetics and Heredity 0.0
Health care sciences and services 0.0

Note: When filters were applied to ‘keyword plus’, reranking occurred to reveal prominent concepts strongest in conveying information revealing ‘prevalence’ as the highest, alongside ‘foot ulceration’ and ‘complications’. In subject categories, top 3 were clinical neurology, neuroscience and biochemistry, and molecular biology revealing which subjects conveyed information best as a hub. This was important to compare against bottom 3, where we identified low communicators/conveyers of information; primary health care, genetics and heredity and health care sciences and services.

3.3. Authors and Papers

3.3.1. Core and Emerging

Recurring authors Azmi, Boulton, Devigili, Dyck, Feldman, Lauria, Malik, Sumner, Tesfaye, Themistocleous, and Young were revealed through high output and preferred citations (within dataset; ‘local citations’) of prominent papers. First authors with established and recognised contribution became readily visible through output. Conversely, ‘global citations’ (counted citations within search WoS repository) revealed authors, Backonja, Dyck, Iqbal, Lauria, Rosenberger, Young, and Zaharia, to be influential beyond the local dataset. New entrants in ‘normalised local citations’ and m‐index global rate show distinct overlap with Croosu and Røikjer as recent influential contributors. Collectively, these authors shaped the corpus (See Supporting Information S4: Tables S7–S9 and S12). Total articles of the top‐5 authors introduced Petropoulos and Ponirakis as important contributors in output (Figure 2). Fractionalised articles of top‐5 authors introduced Bril and Zochodne (Figure 3). Boulton, Lauria and Malik remained commonly known figures.

FIGURE 2.

FIGURE 2

Total articles per author; top 5 present across 1991–2023.

FIGURE 3.

FIGURE 3

Fractionalised articles per author; top 5 present across 1991–2023.

The citations using historiography (Figure 4) further highlighted Sumner, Devigili, Petropoulos and Ponirakis as influential authors (latter two from 2014 onwards). Author's most active periods (peak output or seminal work within dataset) have been tabulated (see Table 6).

FIGURE 4.

FIGURE 4

Sources impact by m‐index measure (within dataset); m‐index communicates relevance over time, thus an m‐index of pain (11) over an 11‐year period has an impact of 1, comparatively, m‐index of journal of peripheral nervous system (13) over a 23‐year period, has impact of 0.57. Overall range was 0.52–1.00: Recency this revealed the emergent knowledge structures. Critically, we see Cell: Stem cell and International Journal of Molecular Medicine outperform Diabetic Medicine and Diabetes Care. Neurology and pain high rate scores in m‐index impact measure, in their respective time frames, indicate increasing value. Recent publication (2022) by Ethiopian authors in the Irish Journal of Medicine accounted for the presence of our outlier in higher Irish Jorunal of Medical Science representation.

TABLE 6.

Summary of authors' production over time between 1991 and 2023.

Authors Division (period)

Context and interpretation

Citation per year refers to peak across authors

Malik and Boulton

Young and Veves

1991–2023

1991–2013

Longest producing research across pertinent search terms.

High citation paper in 1993 identified ‘earliest nexus’.

Youngs' larger prospective study (1993–1994) built upon Dyck et al. platform [83].

Tesfaye et al. [10, 84, 85, 86] contributed significantly within this period.

Boulton, Young and Veves occupied first half of period.

Malik occupied second half.

Lauria and Sommer

Polydefkis

2005–2022

2003–2018

Consistent output with high citations post‐2005.

Lauria built upon McArthur et al. [51] seminal work in 1998 transform into core guidance (2008–2010) [44, 70] particularly with intraepidermal nerve fibre density.

Sommer and Polydefkis overlapped in discrete periods sharing authorship.

Petropoulos, Ponirakis, Alam and Marshall

Azmi and Ferdousi

2014–2023

2015–2021

Concentrated period of accelerating output, shared authorship, both 2015 and 2021 noted high citation articles.

Malik output increased with 2018 and 2021 providing highly cited papers.

Note: Key authors in each period scored higher on a variety of performance metrics. Tranches provide insight into which authors help influence each period.

3.4. Journals

3.4.1. Exploring Sources

The most established intellectual structures (sources) were Journals of Diabetic Medicine and Diabetes Care, suppling n = 71 key articles. The emergence of The journal of peripheral neuropathy (JPN), neurology, and muscle and nerve showed supporting structures where interest was expanding (See Figure 5; Supporting Information S4: Table S16).

FIGURE 5.

FIGURE 5

Across period 1991–2023 core sources (journals) represented main intellectual structure of research. Bradford’s law batches the cumulative frequency of highest performing journals. Green zone indicates core journals of key papers. Yellow zone represents influential journals (either increasing/decreasing relevant output), Diabetic Medicine (36) and Diabetes Care (35) represented the strongest pillars. Journal of peripheral neuropathy (20), neurology (19) and muscle and nerve (17) highlight promising intellectual structures.

The m‐index (See Figure 4) revealed journals of pain, molecular sciences, cell: stem cell, and nature reviews neurology achieved the highest rate of 1: High contemporaneousness. Diabetes Care (0.93), Diabetic Medicine (0.79), and JPN (0.57) rates were respectively lower. Focus on neuropathic pain and molecular components within these articles demonstrated increasing prominence closer towards 2023. Applications of genomics to prognostication, stratification, screening, and diagnosis within podiatric medicine were embryonic [87, 88].

Care and Medicine represented core sources persistent across the entire period. Figure 3 shows eminent fields (subject categories) providing highest cited literature associated to search terms.

3.4.2. Co‐Citation

Network analysis of journals (Supporting Information S9; SF1) demonstrated two major themes (See Supporting Information S6: Figures S5 and S6):

  1. Management of Diabetes (Clinic‐centric): Represented by journals Diabetes Care, Diabetic Medicine, Diabetologia, Diabetes Research Clinical Practice, New England Journal of Medicine, Diabetes and its Complication, Diabetes Metabolism Research and The Lancet.

  2. Neuroscience (Scientific‐centric): Represented by neurology, muscle and nerve, pain, diabetes, brain, journal of neurology, neurosurgery and psychiatry, annual of neurology, peripheral nervous system and journal of neuroscience.

The concepts of brain, periphery, and pain became the prime focus of research inheriting both management and care legacy with journals neurology and diabetes care being the least insular sources.

3.5. Core Institutions

The ranked breakdown of institutions shows the concentration of productivity (Table 7) highlighting The University of Manchester being a major research hub alongside Harvard and Aalborg. Institutions in England, Denmark and USA presented the most influence in shaping the corpus. Italy, Qatar, Germany, and France all featured within the top 20 (Supporting Information S4: Table S22).

TABLE 7.

Top 5 affiliations of authors.

Affiliation Frequency of affiliation
University of Manchester 75
Harvard University 44
Aalborg University 41
Johns Hopkins University 37
Aarhus University 35

Note: N8 partnership had n = 55 but was removed as this was not a single institution adding confounding to results. Frequency of affiliation refers to the sum of authors times their institution. For The University of Manchester, across all papers from 1993 to 2023, shows 75 counts of authors associated to this institution. This helps identify research hubs for relevant research.

3.6. Core Output Across Periods

Influential papers were categorised into five tranches, each reflecting recurring topics, major trials and evolving research priorities:

  1. 1991–1998; research focused on enhancing assessments and diagnosis. Large prospective trials in United Kingdom and United States of America (Rochester and Seattle) generated primary evidence, favouring cross‐sectional study designs. Nerve conduction and vibratory assessment featured more prominently, and research was driven by clinical need and expertise. Diabetes Care and Diabetologia were the leading journals.

  2. 2001–2005; evolution towards evaluating and verifying these new assessments/approaches; smaller cohort studies began establishing preference towards quantitative sensory testing. The period responded to evidence heterogeneity, study designs, and quality. Reliance on consensus driven expertise alongside review studies for assessment, screening, and diagnostic criteria translated into practical guidance.

  3. 2008–2015; saw invasive assessment skin biopsy emerge, with recommendation and guidance. Small‐fibre neuropathy became vogue. Increasingly, neurophysiology and neuroscience were contributing more evidence with clinical diabetes research giving way to clinical neurology. Peripheral nerve society and pain journal gained prominence.

  4. 2016–2019; molecular medicine entered the scene and sensory phenotyping gained momentum. Painful neuropathy, prediabetes diagnosis, and glycaemic management for DFC prevention gained focus. Channelopathies and genetic association pertaining to small fibre neuropathy emerged and larger cohort studies were appearing from Germany.

  5. 2020–2023; phenotype stratification was considered a viable approach to targeted pain management. Case–control studies became more prominent, but vastly smaller participant numbers compared with tranche 1 prospective studies. Point‐of‐care testing was more explicit and vibratory assessments re‐entered vogue. Translation medicine from Denmark and Netherlands introduced new approaches to remedy reproducibility challenges. Large public dataset, clinical health records and genetic repositories were increasing in visibility alongside scientific analysis at scale. A formal Delphi process enhanced expert consensus on assessment, classification, diagnostic criterion and management. Mitochondrial research alongside neuroscience was reflected by Molecular Sciences and Neural Transmission journals (See Supporting Information S5: Tables S24 and S25 for deeper breakdown).

3.7. Trends and Topic: Recurring, Emergent and Subtopic

  • Preventative approaches were underdeveloped/developing

    • Early detection desirable/attempted

    • Remedy sought to rectify delayed detection/under‐diagnosis

  • Detecting preclinical signs remained challenging

    • Point‐of‐care/In situ methods lack consistency, variability in diagnostic criteria

    • Absence of assessment focused randomised control trials (RCTs); investigative rigour missing

  • Clinical Management preference

    • Concentration of authors/institutions

    • The need to diversify thought, population and setting

  • Nomenclature predominantly clinically‐centric

    • Neuroanatomical distribution remained the primary stratification approach

    • Nuanced pathological detail missing/incomplete; better phenotyping needed

  • Reproducibility challenges persistent

    • Role reform in/across disciplines; research‐practice gap notable

    • Standardisation lacking

Influential literature, highlighted by the historiography and high‐rate m‐index authors, was explored with greater scrutiny. Topics were discerned accordingly reflecting recurring frequency. Explicitly, literature reported the value in early diagnosis; contemporary articles and reviews expressed need for robust preventative strategies. Instrumentation, although comprehensive for general neurological assessment, favoured late‐stage manifestation in PLWD; early‐stage presentation remained difficult to capture. Standardised assessment application across research designs suffered from high heterogeneity and inconsistency. Randomised control trials comparing investigative approaches did not feature in top 20. Clinical manifestation shaped nomenclature and stratification, with authors relying upon these terms to categorise patients, in particular employing neuroanatomical distribution. Over the 30 year period, variations in reproducibility were due to differences in instrumentation and assessment thresholds. Evolving research in pain and painless neuropathy highlighted emerging use of molecular characterisation; however, preference using neuroanatomical distribution to classify DPN remained dominant. Subsequently, risk profiling and stratified management appeared as key priorities.

4. Discussion

4.1. Overview

This study successfully met our objectives by analysing a disease‐focused classification with preventative and prognostic potential. We mapped the research landscape by examining various constituents, authors, institutions and countries. Our findings chartered the existing landscape and illuminated emerging trends and gaps, providing a foundation for future research. Observational study design dominated the period; articles and reviews were most prevalent document types averaging an age ∼12 years since publication. Prospective, longitudinal and cohort trial studies [6, 39, 41, 50] exerted a strong influence within the corpus, potentially obscuring newer technologies and study designs [89, 90]. Given the extent of uncertainty between measures, reliance upon dated research and design preference does raises ethical concerns [91]. Liu et al. (2019) [92] noted similar trend, with 14 of 16 studies in their meta‐analysis using cross‐sectional designs, therefore deriving causal relationships is challenging using observational studies [93, 94], potentially accounting for slow progress across fields and period. As such, value and influence should be appreciated cautiously and may account for alternative research design selection.

From 2020, case–control design gained traction in subgroup discrimination (e.g., nonpainful vs. painful neuropathy) [48, 67]. Reviews, position and consensus statements [57, 68] relied heavily on established researcher hubs to consolidate emergent trends [8, 10, 56, 57, 58, 59, 60, 61, 62] and shape diagnostic criterion [10, 56] reflecting conceptualisation, progression and mobilisation of key author knowledge and influence. However, unstructured reviews weakened their value [8, 10, 56, 60, 62], prompting more rigorous Delphi method by Ziegler et al. [57]. Scottish Intercollegiate Guidelines Network (SIGN) 116 were updated last in 2017 [95], NICE (UK) Diabetic Foot Guidelines [NG19] in 2019 [96], American and Australian in 2021 [97, 98] and IWGDF in 2023 [11, 12]. The American, Australian and IWGDF reflect partial elements in language and tools; however, disagreement remains in low/no‐risk screening approaches [99, 100]. Appraisal update of America guidelines identified future research pathway into painful DPN and recognised importance of DPN prevention [100]. UK clinical guidelines should integrate modern research findings [32, 101], particularly as new classification systems emerge, integrating pathophysiological understanding, to refine sensory profiling, risk categorisation and reduce vagueness [53, 102] (especially within low/no‐foot risk groups). To address experimental evidence deficit, international, multicentre and randomised control trials (RTCs), leveraging cutting edge‐techniques (e.g., molecular subtyping [58]) are necessary to reduce uncertainty but appear lacking in this field.

Most instruments relied upon symptom scoring (Table 3). The absence of validated clinical instruments focused on lower limb and sensory aspects was notable. Although systematic approaches (e.g., quantitative sensory testing [QTS]) offer structure for replication [103, 104], they remain time‐consuming and may not capture preclinical symptoms effectively. Validated instrumentation could standardise data collection in health records, supporting pattern recognition to aid earlier risk stratification. Despite their value in assisting assessment [10, 57, 68], instruments are not yet embedded in guideline recommendations [11, 12]. The persistent gap in reliable point‐of‐care screening indicates an incomplete capacity for early risk detection.

Keyword analysis revealed recurring concepts of risk, prevalence and complications (Table 4), emphasising the difficultly in achieving meaningful diagnostic and screening solutions. Western‐centric population cohort were overrepresented [39, 49, 54, 105, 106], limiting generalisability of risk factors research into DPN. Corneal confocal microscopy, despite stringent publication screening to exclude, was well‐represented, reinforcing its diagnostics potential in small fibre neuropathy [107, 108, 109, 110]. Surprisingly, lower limb‐centric concepts were underrepresented, suggesting broad terminology persists where precise, nuanced classification may enhance risk stratification. Without standardised foot and ankle diagnostic tool (with equivocal performance), risk classification will remain nonspecific.

Authors preference for general terms (e.g., diabetic neuropathy) over granular subdivision (e.g., small fibre neuropathy) (Table 4), suggest prioritisation of accessibility over specificity. Centrality measures demonstrated shared understanding across fields (Table 5), although helpful for interdisciplinary collaboration, greater precision in terminology could support clearer specificity of focus therefore enhance staging and progression DPN models [24, 111, 112, 113, 114], thus reduce uncertainty.

Analysis identified formal research hubs and influential authors [6, 8, 9, 10, 39, 40, 41, 43, 44, 50, 53, 54, 56, 59, 62, 65, 70, 115], revealing stable and emerging contributors offering new research direction [47, 48, 67]. Prominent contributors reflected cross‐field links and shared focus [107, 108, 109, 110, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129], revealing interface between concepts and collaborations. Emergent authors highlighted new research direction/contributions [47, 48, 67]. Highly cited research (Figure 6) reflected corpus preference towards scientific approaches nearer 2023; co‐citation network analysis visualising journals relationships (Figure S8) demonstrated increased neuroscience and peripheral nerve focus as core sources. Diabetes management and neuroscience were the overarching groupings for journals, the latter favouring reproducible methodologies. The USA, England and Germany have consistently been the leading contributors, whereas Denmark emerged as a noteworthy contributor (Table 7) (Canada, Italy and Qatar also resided within top 10). European studies increasingly prioritised early DSPN diagnosis [48, 60], with international consensus on definitions developing from ∼2010 [10]. Contemporary publications resided within pain, molecular sciences, cell: stem cell and nature reviews neurology focusing upon pain management and pathological mechanism [46, 59, 60], addressing subjectivity, heterogeneity (presentation) or variable diagnostic criterion [2, 68, 69].

FIGURE 6.

FIGURE 6

Historiography showing document titles and directed graph of referencing. Each node shows document and citation influence with arrow highlighting which document referenced one another. Larger nodes were cited most across local and global datasets. Evolution of topics demonstrates journey through vibration perception thresholds (1994), risk‐factors (1997), epidermal nerve fibre density (1998), screening (2001), quantitative sensory testing (2003), skin biopsy (2005), small nerve fibre (2008), peripheral nerve biopsy (2010) and quantitative sensory testing (2013) [in pain].

Methodological advancements from 1998 onwards included intraepidermal nerve density sampling [44, 51] (Figure 6) and corneal confocal microscopy, in particular for small fibre neuropathy [65], marking a shift from invasive diagnostics. Consequently, then shaping detection and pain management approaches, for example, medicines optimisation [57, 58, 59, 60, 100]. By 2022, revised QST and molecular characterisation aimed to improve classification and screening accuracy [48, 67]. The period post‐2016, reflected adoption of novel technologies to refine polyneuropathy classification. Emphasis upon neural transmission, dysfunction and form of diabetes impacted neuromodulation and neuroregeneration [130]. Recent research suggests neurological‐specific biobanking and next‐generation sequencing (NGS) (e.g., single cell sequencing), could standardise diagnostic approaches, remedy QST limitation and enable better reproducibiligty [131]. Despite its dominance, monofilament testing remains controversial likely due to reliability concerns [132, 133], thus emphasising the need for consistent quantification to guide screening and cost‐effectiveness assessments.

4.2. Podiatric Relevance

Management of DFU necessitates use of multidisciplinary teams (MDTs) [134, 135, 136, 137], with podiatrists playing a central role in screening, risk classification, monitoring, management and prevention [134, 138, 139, 140, 141]. However, the lack of standardised sensory phenotyping complicates accurate risk assessment [142], forcing specialists to wait for late‐stage confirmatory manifestation.

Emerging risk prediction tools offer potential solutions [143, 144, 145]. Haque et al. [143] nomogram‐based severity predictor (97.95% accuracy) leveraged lower‐limbs assessments, drawn from Michigan Neuropathy Screening Instrument (MNSI), but no podiatric‐specific tool attained prominence within research corpus. Existing instruments, primarily from neurology and neuroscience, may need to be repurposed; results herein reveal an abundance of research instruments to select from (Table 3). Effective screening must move beyond neuroanatomical distribution ensuring tools.

  1. mitigate perception biases [47]

  2. maintain high accuracy [48, 67], and

  3. enable non/minimally invasively point‐of‐care assessment

National guidelines lack instrumentation and prediction tool recommendations (however, nomograms have not yet been validated), suggesting a disconnect between pertinent research and practice [11, 12]. Incorporating such measurements may provide liable data to address bias towards monofilament testing. This also suggests that vibration testing remains underutilised, despite significant sensitivity in prediabetic population [57, 60].

4.2.1. Implication to Screening, Monitoring, Diagnostics and Assessment Approaches

The absence of optimal screening and establish diagnostic scrutiny continues to contribute to DPN underdiagnosis [57, 146]. Novel approaches, such as functional MRI for pain discrimination, remain impractical for community settings [47, 147]. However, genetic screening for channelopathies could identify high‐risk individuals (anticipated to experience severe symptoms) to receive early intervention [46, 54, 148], whereas whole‐genome sequencing (WGS) may further refine aetiological classification across peripheral neuroapathies [45, 54]. Lower‐limb specialists could integrate genetic data interpretation into clinical monitoring, enhancing early detection and risk stratification.

Vibratory assessments featured prominently as a concept (Supporting Information S6: Figure S13) and within influential publications. Of which, ∼16% (n = 6) [38, 39, 40, 42, 50, 52], were explicitly reported with consistent methodology. Comparatively, ∼13% (n = 5) [38, 39, 40, 52, 56] employed QST, which included both pressure (monofilament) and autonomic assessment; despite widespread use, monofilament lacked clear conceptual distinction, likely attributable to sensitivity concerns [149], inconsistent testing site [150] and scrutiny over thresholds [49, 132]. Vibratory assessment value vacillated between tantalising ‘screening tool’ [50], ‘limited value’ [151] and ‘important for early‐stage disease’ [57, 60]. Development of normative reference for age likely improved categorisation utility [40, 57, 152]; future thresholds require country or ethnicity‐specificity to improve accuracy [153]. The Ipswich touch test (IpTT) [154, 155, 156, 157] was noticeably absence, reinforcing the corpus preference for objective over subjective measures despite recommended screening tool in IWGDF [11, 12]. Emerging approaches, such as vibration threshold tracking (VTT) in Denmark [67], show promise as they navigate issues of neural accommodations that adapt during extended testing [103, 104]. However, before clinical implementation can occur, consensus on standardisation is required.

4.3. Comparison to Contemporary Work

This bibliometric analysis aligns with Zha BS et al. 2019 [22] and Deng et al. 2022 [158], confirming key contributing countries and topics. Recent work by Tang et al. [86] similarly identified dominant topics of risk factors, epidemiology, diagnosis and complications with genetic research gaining importance [24, 58, 86, 111]. The PROTECT Study Survey 2 [159] identified podiatrists as key players in neurological assessments, research into structured deep phenotyping could standardise these approaches [160, 161]. In turn, helping to unmask insights currently inaccessible in clinical records to amplify ‘Omic investigations [160, 161, 162, 163] where ongoing challenges persist [164, 165].

4.4. Limitations

The exploratory design precluded in‐depth paper analysis, limiting explanatory depth. Citations, a crude metric, cannot reflect quality or impact [166, 167]. All performance metrics should be viewed cautiously. Single screening author limited generalisability; however, this was partially offset through findings discussion (consensus between authors) to taper inherent bias. Institutions were disambiguated by the software; therefore, it is possible that some were either over or under counted. Using a single database may have caused us to have incomplete publication capture. Future bibliometric designs should consider which research constituents offer the highest informational yield, pertinent to these fields, to inform revised bibliometric protocol design [166]. Topics were manually extracted via single author [BJ] with additional research team input upon finding; full systematic thematic analysis was not employed at this juncture.

4.5. Conclusion

The explored topics, contextualised through synopsis, revealed high desirability for early identification and prevention of DPN. Reproducibility issues have prompted multiple fields (diabetes care and neurology) towards objectifying assessments; focus is upon improving screening and clinical risk prediction in PLWD to minimise DFU. Pre‐2016 period was predominantly clinically‐led research; post‐2016, migration occured towards scientific‐led research designs. This likely reflected new approaches to diagnostics and risk categorisation. Sources revealed subject matter involving molecular medicine, biochemistry and stem cells—particularly for neuropathic pain management for small fibre neuropathy, are of growing interest clinically for medicines optimisation. Further investigation into molecular‐augmented assessments/screening or clinical tools/instrumentation linked with preventative approaches could address areas where paucity of evidence was noted.

Author Contributions

Benjamin M. Jones: conceptualization (equal), date curation (equal), formal analysis (lead), investigation (lead), methodology (equal), project administration (lead), resources (lead), software (lead), supervision (equal), validation (equal), visualisation (lead), writing – original draft (lead), and writing – review and editing (equal). Reuben J. Pengelly: conceptualization (supporting), data curation (equal), formal analysis (supporting), methodology (equal), resources (supporting), software (supporting), supervision (equal), validation (equal), visualisation (supporting), writing – review and editing (equal). Alan M. Borthwick: supervision (equal) and writing – review and editing (equal). Catherine J. Bowen: conceptualization (equal), methodology (equal), supervision (equal), and writing – review and editing (equal).

Conflicts of Interest

Benjamin M. Jones and Reuben J. Pengelly declare no conflicts of interest. Catherine J. Bowen and Alan M. Borthwick are emeritus editors of the Journal of Foot and Ankle Research. C.J.B. is supported by a National Institute of Health Research (NIHR) Senior Investigator Grant (#203706). The views expressed in this publication are those of the authors and not necessarily those of the NIHR.

Supporting information

Supporting Information S1

JFA2-18-e70062-s002.docx (15.1KB, docx)

Supporting Information S2

JFA2-18-e70062-s007.docx (17.2KB, docx)

Supporting Information S3

JFA2-18-e70062-s004.docx (17.6KB, docx)

Supporting Information S4

JFA2-18-e70062-s005.docx (612.8KB, docx)

Supporting Information S5

JFA2-18-e70062-s008.docx (48.8KB, docx)

Supporting Information S6

JFA2-18-e70062-s010.docx (3.4MB, docx)

Supporting Information S7

Supporting Information S8

JFA2-18-e70062-s009.docx (18.6KB, docx)

Figure S1

JFA2-18-e70062-s003.docx (1.6MB, docx)

Figure S2

JFA2-18-e70062-s001.docx (103.1KB, docx)

Table S23

JFA2-18-e70062-s006.docx (15.3KB, docx)

Jones, Benjamin M. , Pengelly Reuben J., Borthwick Alan M., and Bowen Catherine J.. 2025. “Bibliometric Analysis: Insights Into the Podiatric Medicine Landscape of Diabetic Sensory Peripheral Neuropathy and Genomics.” Journal of Foot and Ankle Research: e70062. 10.1002/jfa2.70062.

Funding: The authors received no specific funding for this work.

Data Availability Statement

The authors have nothing to report.

References

  • 1. Lazzarini P. A., Raspovic K. M., Meloni M., and van Netten J. J., “A New Declaration for Feet's Sake: Halving the Global Diabetic Foot Disease Burden From 2% to 1% With Next Generation Care,” Diabetes/Metabolism Research and Reviews 40, no. 3 (2024): e3747, 10.1002/dmrr.3747. [DOI] [PubMed] [Google Scholar]
  • 2. Elafros M. A., Andersen H., Bennett D. L., et al., “Towards Prevention of Diabetic Peripheral Neuropathy: Clinical Presentation, Pathogenesis, and New Treatments,” Lancet Neurology 21, no. 10 (2022): 922–936, 10.1016/s1474-4422(22)00188-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Jaskulski S., Nuszbaum C., and Michels K. B., “Components, Prospects and Challenges of Personalized Prevention,” Frontiers in Public Health 11 (2023): 1075076, 10.3389/fpubh.2023.1075076. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. van Netten J. J., Bus S. A., Apelqvist J., et al., “Definitions and Criteria for Diabetes‐Related Foot Disease (IWGDF 2023 Update),” Diabetes/Metabolism Research and Reviews 40, no. 3 (2024): e3654. [DOI] [PubMed] [Google Scholar]
  • 5. Boulton A. J. M., Kubrusly D. B., Bowker J. H., et al., “Impaired Vibratory Perception and Diabetic Foot Ulceration,” Diabetic Medicine 3, no. 4 (1986): 335–337, 10.1111/j.1464-5491.1986.tb00775.x. [DOI] [PubMed] [Google Scholar]
  • 6. Dyck P. J., Kratz K. M., Karnes J. L., et al., “The Prevalence by Staged Severity of Various Types of Diabetic Neuropathy, Retinopathy, and Nephropathy in a Population‐Based Cohort: The Rochester Diabetic Neuropathy Study,” Neurology 43, no. 4 (1993): 817–824, 10.1212/wnl.43.4.817. [DOI] [PubMed] [Google Scholar]
  • 7. Meijer J. W. G., Smit A. J., Sonderen E. V., Groothoff J. W., Eisma W. H., and Links T. P., “Symptom Scoring Systems to Diagnose Distal Polyneuropathy in Diabetes: The Diabetic Neuropathy Symptom Score,” Diabetic Medicine 19, no. 11 (2002): 962–965, 10.1046/j.1464-5491.2002.00819.x. [DOI] [PubMed] [Google Scholar]
  • 8. Boulton A. J. M., Malik R. A., Arezzo J. C., and Sosenko J. M., “Diabetic Somatic Neuropathies,” Diabetes Care 27, no. 6 (2004): 1458–1486, 10.2337/diacare.27.6.1458. [DOI] [PubMed] [Google Scholar]
  • 9. Devigili G., Tugnoli V., Penza P., et al., “The Diagnostic Criteria for Small Fibre Neuropathy: From Symptoms to Neuropathology,” Brain 131, no. 7 (2008): 1912–1925, 10.1093/brain/awn093. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Tesfaye S., Boulton A. J. M., Dyck P. J., et al., “Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments,” Diabetes Care 33, no. 10 (2010): 2285–2293, 10.2337/dc10-1303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Bus S. A., Sacco I. C. N., Monteiro‐Soares M., et al., “Guidelines on the Prevention of Foot Ulcers in Persons With Diabetes (IWGDF 2023 Update),” Diabetes/Metabolism Research and Reviews 40, no. 3 (2024): e3651, 10.1002/dmrr.3651. [DOI] [PubMed] [Google Scholar]
  • 12. Schaper N. C., Van Netten J. J., Apelqvist J., et al., “Practical Guidelines on the Prevention and Management of Diabetes‐Related Foot Disease (IWGDF 2023 Update),” Diabetes/Metabolism Research and Reviews 40, no. 3 (2024): e3657. [DOI] [PubMed] [Google Scholar]
  • 13. Carroll M., Al‐Busaidi I. S., Coppell K. J., et al., “Diabetes‐Related Foot Disease Research in Aotearoa New Zealand: A Bibliometric Analysis (1970–2020),” Journal of Foot and Ankle Research 15, no. 1 (2022): 23, 10.1186/s13047-022-00528-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Tehan P. E., Perrin B. M., Lazzarini P. A., Al‐Busaidi I. S., and Carroll M. R., “How Far Has Diabetes‐Related Foot Disease Research Progressed in Australia? A Bibliometric Review (1970–2023),” Journal of Foot and Ankle Research 17, no. 2 (2024): e12012, 10.1002/jfa2.12012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Dong J., Li L., Lu M., Cheng X., and Zhai Y., “Pressure Ulcers in Patients With Diabetes: A Bibliometrics Analysis,” Annals of Palliative Medicine 10, no. 10 (2021): 10515–10526, 10.21037/apm-21-2757. [DOI] [PubMed] [Google Scholar]
  • 16. Shen J.‐M., Chen J., Feng L., and Feng C., “A Scientometrics Analysis and Visualisation of Diabetic Foot Research From 1955 to 2022,” International Wound Journal 20, no. 4 (2023): 1072–1087, 10.1111/iwj.13964. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Chen Z., Liu W., Chen Z., and Li G., “Surgical Management for Diabetic Foot Ulcer: A Bibliometric Study,” Chinese Journal of Plastic and Reconstructive Surgery 2, no. 3 (2020): 149–160, 10.1016/s2096-6911(21)00027-3. [DOI] [Google Scholar]
  • 18. Nolan C. K., Spiess K. E., and Meyr A. J., “Where Art Thou Diabetic Foot Disease Literature? A Bibliometric Inquiry Into Publication Patterns,” Journal of Foot and Ankle Surgery 54, no. 3 (2015): 295–297, 10.1053/j.jfas.2014.04.010. [DOI] [PubMed] [Google Scholar]
  • 19. GOV.UK . Research and Analysis: DHSC's Areas of Research Interest (Department of Health & Social Care, 2023). [Google Scholar]
  • 20. Zhao X.‐P., Li Da, Li C.‐L., Zhang Y.‐Na, Zhao N.‐R., and Xu J.‐X., “Knowledge Mapping of Diabetic Foot Research Based on Web of Science Database: A Bibliometric Analysis,” Medicine 102, no. 26 (2023): e34053, 10.1097/md.0000000000034053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Maliza R., Irham L. M., Pradika J., et al., “Genetic Polymorphism and the Risk of Diabetic Foot: A Bibliometric Analysis From 2011–2021,” International Journal of Public Health 12, no. 4 (2023): 1744–1752, 10.11591/ijphs.v12i4.23028. [DOI] [Google Scholar]
  • 22. Zha M.‐Li, Cai Ji‐Yu, and Chen H.‐L., “A Bibliometric Analysis of Global Research Production Pertaining to Diabetic Foot Ulcers in the Past Ten Years,” Journal of Foot and Ankle Surgery 58, no. 2 (2019): 253–259, 10.1053/j.jfas.2018.08.052. [DOI] [PubMed] [Google Scholar]
  • 23. Zamponi G. W., Striessnig J., Koschak A., and Dolphin A. C., “The Physiology, Pathology, and Pharmacology of Voltage‐Gated Calcium Channels and Their Future Therapeutic Potential,” Pharmacological Reviews 67, no. 4 (2015): 821–870, 10.1124/pr.114.009654. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Prabodha L. B. L., Sirisena N. D., and Dissanayake V. H. W., “Susceptible and Prognostic Genetic Factors Associated With Diabetic Peripheral Neuropathy: A Comprehensive Literature Review,” International Journal of Endocrinology 2018, no. 1 (2018): 8641942–8641949, 10.1155/2018/8641942. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Hivert M.‐F., Jablonski K. A., Perreault L., et al., “Updated Genetic Score Based on 34 Confirmed Type 2 Diabetes Loci Is Associated With Diabetes Incidence and Regression to Normoglycemia in the Diabetes Prevention Program,” Diabetes 60, no. 4 (2011): 1340–1348, 10.2337/db10-1119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Imamura M., Shigemizu D., Tsunoda T., et al., “Assessing the Clinical Utility of a Genetic Risk Score Constructed Using 49 Susceptibility Alleles for Type 2 Diabetes in a Japanese Population,” Journal of Clinical Endocrinology & Metabolism 98, no. 10 (2013): E1667–E1673, 10.1210/jc.2013-1642. [DOI] [PubMed] [Google Scholar]
  • 27. Sullivan S. D., Jablonski K. A., Florez J. C., et al., “Genetic Risk of Progression to Type 2 Diabetes and Response to Intensive Lifestyle or Metformin in Prediabetic Women With and Without a History of Gestational Diabetes Mellitus,” Diabetes Care 37, no. 4 (2014): 909–911, 10.2337/dc13-0700. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Wang X., Strizich G., Hu Y., Wang T., Kaplan R. C., and Qi Q., “Genetic Markers of Type 2 Diabetes: Progress in Genome‐Wide Association Studies and Clinical Application for Risk Prediction,” Journal of Diabetes 8, no. 1 (2016): 24–35, 10.1111/1753-0407.12323. [DOI] [PubMed] [Google Scholar]
  • 29. Miranda‐Lora A. L., Vilchis‐Gil J., Juárez‐Comboni D. B., Cruz M., and Klünder‐Klünder M., “A Genetic Risk Score Improves the Prediction of Type 2 Diabetes Mellitus in Mexican Youths But Has Lower Predictive Utility Compared With Non‐Genetic Factors,” Frontiers in Endocrinology 12 (2021): 647864, 10.3389/fendo.2021.647864. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Koo M. and Lin S.‐C., “An Analysis of Reporting Practices in the Top 100 Cited Health and Medicine‐Related Bibliometric Studies From 2019 to 2021 Based on a Proposed Guidelines,” Heliyon 9, no. 6 (2023): e16780, 10.1016/j.heliyon.2023.e16780. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Donthu N., Kumar S., Mukherjee D., Pandey N., and Lim W. M., “How to Conduct a Bibliometric Analysis: An Overview and Guidelines,” Journal of Business Research 133 (2021): 285–296, 10.1016/j.jbusres.2021.04.070. [DOI] [Google Scholar]
  • 32. NICE . Diabetic Foot Problems: Prevention and Management [NG19], accessed, January 13, 2024, https://www.nice.org.uk/guidance/ng19/chapter/Recommendations.
  • 33. Ouzzani M., Hammady H., Fedorowicz Z., and Elmagarmid A., “Rayyan—A Web and Mobile App for Systematic Reviews,” Systematic Reviews 5 (2016): 1–10, 10.1186/s13643-016-0384-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Borthwick A. M., Nancarrow S., Bristow I., and Bowen C., “Contested Role Boundaries and Professional Title: Implications of the Independent Review of Podiatric Surgery in Australia,” Journal of Foot and Ankle Research 17, no. 4 (2024): e70007, 10.1002/jfa2.70007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Aria M. and Cuccurullo C., “Bibliometrix: An R‐Tool for Comprehensive Science Mapping Analysis,” Journal of Informetrics 11, no. 4 (2017): 959–975, 10.1016/j.joi.2017.08.007. [DOI] [Google Scholar]
  • 36. Mathieu B., Sebastien H., and Mathieu J.. “Gephi: An Open Source Software for Exploring and Manipulating Networks,” in Proceedings of the International AAAI Conference on Web and Social Media [ICWSM‐09], ed. Cohen W. and Nicolov N. (PKP Publishing Services Network, 2009), 10.1609/icwsm.v3i1.13937. [DOI] [Google Scholar]
  • 37. van Eck N. J. and Waltman L., “Citation‐Based Clustering of Publications Using CitNetExplorer and VOSviewer,” Scientometrics 111, no. 2 (2017): 1053–1070, 10.1007/s11192-017-2300-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Tesfaye S., Stevens L. K., Stephenson J. M., et al., “Prevalence of Diabetic Peripheral Neuropathy and Its Relation to Glycaemic Control and Potential Risk Factors: The EURODIAB IDDM Complications Study,” Diabetologia 39, no. 11 (1996): 1377–1384, 10.1007/s001250050586. [DOI] [PubMed] [Google Scholar]
  • 39. Young M. J., Boulton A. J. M., Macleod A. F., Williams D. R. R., and Sonksen P. H., “A Multicentre Study of the Prevalence of Diabetic Peripheral Neuropathy in the United Kingdom Hospital Clinic Population,” Diabetologia 36, no. 2 (1993): 150–154, 10.1007/bf00400697. [DOI] [PubMed] [Google Scholar]
  • 40. Themistocleous A. C., Ramirez J. D., Shillo P. R., et al., “The Pain in Neuropathy Study (PiNS): A Cross‐Sectional Observational Study Determining the Somatosensory Phenotype of Painful and Painless Diabetic Neuropathy,” Pain 157, no. 5 (2016): 1132–1145, 10.1097/j.pain.0000000000000491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41. Feldman E. L., Stevens M. J., Thomas P. K., Brown M. B., Canal N., and Greene D. A., “A Practical Two‐Step Quantitative Clinical and Electrophysiological Assessment for the Diagnosis and Staging of Diabetic Neuropathy,” Diabetes Care 17, no. 11 (1994): 1281–1289, 10.2337/diacare.17.11.1281. [DOI] [PubMed] [Google Scholar]
  • 42. Perkins B. A., Olaleye D., Zinman B., and Bril V., “Simple Screening Tests for Peripheral Neuropathy in the Diabetes Clinic,” Diabetes Care 24, no. 2 (2001): 250–256, 10.2337/diacare.24.2.250. [DOI] [PubMed] [Google Scholar]
  • 43. Sumner C. J., Sheth S., Griffin J. W., Cornblath D. R., and Polydefkis M., “The Spectrum of Neuropathy in Diabetes and Impaired Glucose Tolerance,” Neurology 60, no. 1 (2003): 108–111, 10.1212/wnl.60.1.108. [DOI] [PubMed] [Google Scholar]
  • 44. Lauria G., Bakkers M., Schmitz C., et al., “Intraepidermal Nerve Fiber Density at the Distal Leg: A Worldwide Normative Reference Study,” Journal of the Peripheral Nervous System 15, no. 3 (2010): 202–207, 10.1111/j.1529-8027.2010.00271.x. [DOI] [PubMed] [Google Scholar]
  • 45. Blesneac I., Themistocleous A. C., Fratter C., et al., “Rare Na(V)1.7 Variants Associated With Painful Diabetic Peripheral Neuropathy,” Pain 159, no. 3 (2018): 469–480, 10.1097/j.pain.0000000000001116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46. Ślęczkowska M., Almomani R., Marchi M., et al., “Peripheral Ion Channel Gene Screening in Painful‐ and Painless‐Diabetic Neuropathy,” International Journal of Molecular Sciences 23, no. 13 (2022): 7190, 10.3390/ijms23137190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47. Croosu S. S., Røikjer J., Mørch C. D., Ejskjaer N., Frøkjær J. B., and Hansen T. M., “Alterations in Functional Connectivity of Thalamus and Primary Somatosensory Cortex in Painful and Painless Diabetic Peripheral Neuropathy,” Diabetes Care 46, no. 1 (2023): 173–182, 10.2337/dc22-0587. [DOI] [PubMed] [Google Scholar]
  • 48. Røikjer J., Croosu S. S., Frøkjær J. B., et al., “Perception Threshold Tracking: Validating a Novel Method for Assessing Function of Large and Small Sensory Nerve Fibers in Diabetic Peripheral Neuropathy With and Without Pain,” Pain 164, no. 4 (2023): 886–894, 10.1097/j.pain.0000000000002780. [DOI] [PubMed] [Google Scholar]
  • 49. Adler A. I., Boyko E. J., Ahroni J. H., Stensel V., Forsberg R. C., and Smith D. G., “Risk Factors for Diabetic Peripheral Sensory Neuropathy—Results of the Seattle Prospective Diabetic Foot Study,” Diabetes Care 20, no. 7 (1997): 1162–1167, 10.2337/diacare.20.7.1162. [DOI] [PubMed] [Google Scholar]
  • 50. Young M. J., Breddy J. L., Veves A., and Boulton A. J. M., “The Prediction of Diabetic Neuropathic Foot Ulceration Using Vibration Perception Thresholds: A Prospective Study,” Diabetes Care 17, no. 6 (1994): 557–560, 10.2337/diacare.17.6.557. [DOI] [PubMed] [Google Scholar]
  • 51. McArthur J. C., Stocks E. A., Hauer P., Cornblath D. R., and Griffin J. W., “Epidermal Nerve Fiber Density: Normative Reference Range and Diagnostic Efficiency,” Archives of Neurology 55, no. 12 (1998): 1513–1520, 10.1001/archneur.55.12.1513. [DOI] [PubMed] [Google Scholar]
  • 52. Shun C.‐T., Chang Y.‐C., Wu H.‐P., et al., “Skin Denervation in Type 2 Diabetes: Correlations With Diabetic Duration and Functional Impairments,” Brain 127, no. 7 (2004): 1593–1605, 10.1093/brain/awh180. [DOI] [PubMed] [Google Scholar]
  • 53. Zaharia O. P., Strassburger K., Strom A., et al., “Risk of Diabetes‐Associated Diseases in Subgroups of Patients With Recent‐Onset Diabetes: A 5‐Year Follow‐Up Study,” Lancet Diabetes & Endocrinology 7, no. 9 (2019): 684–694, 10.1016/s2213-8587(19)30187-1. [DOI] [PubMed] [Google Scholar]
  • 54. Themistocleous A. C., Baskozos G., Blesneac I., and Comini M., “Investigating Genotype‐Phenotype Relationship of Extreme Neuropathic Pain Disorders in a UK National Cohort,” Brain Communications 5, no. 2 (2023): 21, 10.1093/braincomms/fcad037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55. Gregg E. W., Sorlie P., Paulose‐Ram R., Gu Q., and Eberhardt M. S., “Prevalence of Lower‐Extremity Disease in the U.S. Adult Population 40 Years of Age With and Without Diabetes: 1999–2000 National Health and Nutrition Examination Survey,” Diabetes Care 27, no. 7 (2004): 1591–1597, 10.2337/diacare.27.7.1591. [DOI] [PubMed] [Google Scholar]
  • 56. Iqbal Z., Azmi S., Yadav R., et al., “Diabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and Pharmacotherapy,” Clinical Therapeutics 40, no. 6 (2018): 828–849, 10.1016/j.clinthera.2018.04.001. [DOI] [PubMed] [Google Scholar]
  • 57. Ziegler D., Tesfaye S., Spallone V., Gurieva I., and Al Kaabi J., “Screening, Diagnosis and Management of Diabetic Sensorimotor Polyneuropathy in Clinical Practice: International Expert Consensus Recommendations,” Diabetes Research and Clinical Practice 186 (2022): 109063, 10.1016/j.diabres.2021.109063. [DOI] [PubMed] [Google Scholar]
  • 58. Sopacua M., Hoeijmakers J. G. J., Merkies I. S. J., Lauria G., Waxman S. G., and Faber C. G., “Small‐Fiber Neuropathy: Expanding the Clinical Pain Universe,” Journal of the Peripheral Nervous System 24, no. 1 (2019): 19–33, 10.1111/jns.12298. [DOI] [PubMed] [Google Scholar]
  • 59. Rosenberger D. C., Blechschmidt V., Timmerman H., Wolff A., and Treede R.‐D., “Challenges of Neuropathic Pain: Focus on Diabetic Neuropathy,” Journal of Neural Transmission 127, no. 4 (2020): 589–624, 10.1007/s00702-020-02145-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60. Burgess J., Frank B., Marshall A., and Khalil R. S., “Early Detection of Diabetic Peripheral Neuropathy: A Focus on Small Nerve Fibres,” Diagnostics 11, no. 2 (2021): 165, 10.3390/diagnostics11020165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61. Lacomis D., “Small‐Fiber Neuropathy,” Muscle & Nerve 26, no. 2 (2002): 173–188, 10.1002/mus.10181. [DOI] [PubMed] [Google Scholar]
  • 62. Backonja M. M., Attal N., Baron R., Bouhassira D., Drangholt M., and Dyck P. J., “Value of Quantitative Sensory Testing in Neurological and Pain Disorders: NeuPSIG Consensus,” Pain 154, no. 9 (2013): 1807–1819, 10.1016/j.pain.2013.05.047. [DOI] [PubMed] [Google Scholar]
  • 63. Røikjer J., Jensen M. H., Vestergaard P., Sørensen A. M., Laursen H. V. B., and Ejskjær N., “Twenty Years With Diabetes and Amputations: A Retrospective Population‐Based Cohort Study,” Diabetic Medicine 37, no. 12 (2020): 2098–2108, 10.1111/dme.14251. [DOI] [PubMed] [Google Scholar]
  • 64. Røikjer J., Werkman N. C. C., Ejskjaer N., and van den Bergh J. P. W., “Incidence, Hospitalization and Mortality and Their Changes Over Time in People With a First Ever Diabetic Foot Ulcer,” Diabetic Medicine 39, no. 4 (2022): e14725, 10.1111/dme.14725. [DOI] [PubMed] [Google Scholar]
  • 65. Azmi S., Ferdousi M., Petropoulos I. N., and Ponirakis G., “Corneal Confocal Microscopy Identifies Small‐Fiber Neuropathy in Subjects With Impaired Glucose Tolerance Who Develop Type 2 Diabetes,” Diabetes Care 38, no. 8 (2015): 1502–1508, 10.2337/dc14-2733. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66. Røikjer J., Croosu S. S., Hansen T. M., and Frøkjær J. B., “The Co‐Existence of Sensory and Autonomic Neuropathy in Type 1 Diabetes With and Without Pain,” Acta Diabetologica 60, no. 6 (2023): 777–785, 10.1007/s00592-023-02062-7. [DOI] [PubMed] [Google Scholar]
  • 67. Roikjer J., Croosu S. S., Sejergaard B. F., et al., “Diagnostic Accuracy of Perception Threshold Tracking in the Detection of Small Fiber Damage in Type 1 Diabetes,” Journal of Diabetes Science and Technology 8 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68. Pop‐Busui R., Boulton A. J. M., Feldman E. L., et al., “Diabetic Neuropathy: A Position Statement by the American Diabetes Association,” Diabetes Care 40, no. 1 (2017): 136–154, 10.2337/dc16-2042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69. Boulton A. J. M., Vinik A. I., Arezzo J. C., Bril V., and Feldman E. L., “Diabetic Neuropathies: A Statement by the American Diabetes Association,” Diabetes Care 28, no. 4 (2005): 956–962, 10.2337/diacare.28.4.956. [DOI] [PubMed] [Google Scholar]
  • 70. Lauria G., Hsieh S. T., Johansson O., Kennedy W. R., Leger J. M., and Mellgren S. I., “European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the Use of Skin Biopsy in the Diagnosis of Small Fiber Neuropathy. Report of a Joint Task Force of the European Fe‐Deration of Neurological Societies and the Peripheral Nerve Society,” European Journal of Neurology 17, no. 7 (2010): 903‐e49, 10.1111/j.1468-1331.2010.03023.x. [DOI] [PubMed] [Google Scholar]
  • 71. Shy M. E., Frohman E. M., So Y. T., et al., “Quantitative Sensory Testing: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology,” Neurology 60, no. 6 (2003): 898–904, 10.1212/01.wnl.0000058546.16985.11. [DOI] [PubMed] [Google Scholar]
  • 72. Keenan S. P., Guyatt G. H., Sibbald W. J., Cook D. J., Heyland D. K., and Jaeschke R. Z., “How to Use Articles About Diagnostic Technology: Gastric Tonometry,” Critical Care Medicine 27, no. 9 (1999): 1726–1731, 10.1097/00003246-199909000-00005. [DOI] [PubMed] [Google Scholar]
  • 73. Deeks J. J., “Systematic Reviews of Evaluations of Diagnostic and Screening Tests,” BMJ 323, no. 7305 (2001): 157–162, 10.1136/bmj.323.7305.157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74. Jaeschke R., Guyatt G. H., “How Should Diagnostic Tests Be Chosen and Used,” (2001).
  • 75. Mulherin S. A. and Miller W. C., “Spectrum Bias or Spectrum Effect? Subgroup Variation in Diagnostic Test Evaluation,” Annals of Internal Medicine 137, no. 7 (2002): 598–602, 10.7326/0003-4819-137-7-200210010-00011. [DOI] [PubMed] [Google Scholar]
  • 76. Fischer J. E., Bachmann L. M., and Jaeschke R., “A Readers' Guide to the Interpretation of Diagnostic Test Properties: Clinical Example of Sepsis,” Intensive Care Medicine 29, no. 7 (2003): 1043–1051, 10.1007/s00134-003-1761-8. [DOI] [PubMed] [Google Scholar]
  • 77. Schunemann H. J., Oxman A. D., Brozek J., et al., “GRADE: Assessing the Quality of Evidence for Diagnostic Recommendations,” Evidence‐Based Medicine 13, no. 6 (2008): 162–163, 10.1136/ebm.13.6.162-a. [DOI] [PubMed] [Google Scholar]
  • 78. Thiese M. S., “Observational and Interventional Study Design Types; an Overview,” Biochemia Medica 24, no. 2 (2014): 199–210, 10.11613/bm.2014.022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79. Ranganathan P. and Aggarwal R., “Study Designs: Part 1—An Overview and Classification,” Perspectives in Clinical Research 9, no. 4 (2018): 184–186, 10.4103/picr.picr_124_18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80. Rezigalla A. A., “Observational Study Designs: Synopsis for Selecting an Appropriate Study Design,” Cureus 12, no. 1 (2020): e6692, 10.7759/cureus.6692. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81. Dyck P. J., Sherman W. R., Hallcher L. M., et al., “Human Diabetic Endoneurial Sorbitol, Fructose, and Myo‐Inositol Related to Sural Nerve Morphometry,” Annals of Neurology 8, no. 6 (1980): 590–596, 10.1002/ana.410080608. [DOI] [PubMed] [Google Scholar]
  • 82. Dyck P. J., Karnes J., O'Brien P. C., and Swanson C. J., “Neuropathy Symptom Profile in Health, Motor Neuron Disease, Diabetic Neuropathy, and Amyloidosis,” Neurology 36, no. 10 (1986): 1300, 10.1212/wnl.36.10.1300. [DOI] [PubMed] [Google Scholar]
  • 83. Dyck P. J., “Detection, Characterization, and Staging of Polyneuropathy: Assessed in Diabetics,” Muscle & Nerve 11, no. 1 (1988): 21–32, 10.1002/mus.880110106. [DOI] [PubMed] [Google Scholar]
  • 84. Tesfaye S. and Selvarajah D., “Advances in the Epidemiology, Pathogenesis and Management of Diabetic Peripheral Neuropathy,” Diabetes‐Metabolism Research and Reviews 28, no. S1 (2012): 8–14, 10.1002/dmrr.2239. [DOI] [PubMed] [Google Scholar]
  • 85. Tesfaye S., Malik R., Harris N., et al., “Arterio‐Venous Shunting and Proliferating New Vessels in Acute Painful Neuropathy of Rapid Glycaemic Control (Insulin Neuritis),” Diabetologia 39, no. 3 (1996): 329–335, 10.1007/bf00418349. [DOI] [PubMed] [Google Scholar]
  • 86. Tang F., Zhao F., Jiang Y., Zhang T., and Wang B., “Global Hotspots and Trends in Diabetic Peripheral Neuropathy Research From 2011 to 2023,” Medicine 103, no. 32 (2024): e39295, 10.1097/md.0000000000039295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87. Tang Y., Lenzini P. A., Pop‐Busui R., Ray P. R., and Campbell H., “A Genetic Locus on Chromosome 2q24 Predicting Peripheral Neuropathy Risk in Type 2 Diabetes: Results From the ACCORD and BARI 2D Studies,” Diabetes 68, no. 8 (2019): 1649–1662, 10.2337/db19-0109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88. Winsvold B. S., Kitsos I., Thomas L. F., et al., “Genome‐Wide Association Study of 2,093 Cases With Idiopathic Polyneuropathy and 445,256 Controls Identifies First Susceptibility Loci,” Frontiers in Neurology 12 (2021): 789093, 10.3389/fneur.2021.789093. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89. Sempere‐Bigorra M., Brognara L., Julian‐Rochina I., Mazzotti A., and Cauli O., “Relationship Between Deep and Superficial Sensitivity Assessments and Gait Analysis in Diabetic Foot Patients,” International Wound Journal 20, no. 8 (2023): 3023–3034, 10.1111/iwj.14178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90. Talha M., Kyrarini M., and Buriro E. A., “A Survey of the Diagnosis of Peripheral Neuropathy Using Intelligent and Wearable Systems,” Technologies 11, no. 6 (2023): 163, 10.3390/technologies11060163. [DOI] [Google Scholar]
  • 91. Raymond J., Fahed R., and Darsaut T. E., “Ethical Problems of Observational Studies and Big Data Compared to Randomized Trials,” Journal of Medicine and Philosophy: A Forum for Bioethics and Philosophy of Medicine 49, no. 4 (2024): 389–398, 10.1093/jmp/jhae021. [DOI] [PubMed] [Google Scholar]
  • 92. Liu X., Xu Y., An M., and Zeng Q., “The Risk Factors for Diabetic Peripheral Neuropathy: A Meta‐Analysis,” PLoS One 14, no. 2 (2019): e0212574, 10.1371/journal.pone.0212574. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93. Sedgwick P., “Cross Sectional Studies: Advantages and Disadvantages,” BMJ British Medical Journal 348, (March 2014): g2276, 10.1136/bmj.g2276. [DOI] [Google Scholar]
  • 94. Setia M.S., “Methodology Series Module 3: Cross‐Sectional Studies,” Indian Journal of Dermatology 61, no. 3 (2016): 261–264, 10.4103/0019-5154.182410. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95. Scottish Intercollegiate Guidelines N . 116 Management of Diabetes: A National Clinical Guideline (SIGN, 2017). [Google Scholar]
  • 96. NICE . Diabetic Foot Problems Prevention and Management. NICE Guideline (NG19), Vol. NG19 (National Institute for Clinical Excellence, 2019). [Google Scholar]
  • 97. American Diabetes Association Professional Practice Committee , “Retinopathy, Neuropathy, and Foot Care: Standards of Medical Care in Diabetes—2022,” supplement, Diabetes Care 45, no. S1 (2021): S185–S194, 10.2337/dc22-s012. [DOI] [PubMed] [Google Scholar]
  • 98. Kaminski M. R., Golledge J., Lasschuit J. W. J., et al., “Australian Guideline on Prevention of Foot Ulceration: Part of the 2021 Australian Evidence‐Based Guidelines for Diabetes‐Related Foot Disease,” Journal of Foot and Ankle Research 15, no. 1 (2022): 53, 10.1186/s13047-022-00534-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99. Lazzarini P. A., Raspovic A., Prentice J., et al., “Australian Evidence‐Based Guidelines for the Prevention and Management of Diabetes‐Related Foot Disease: A Guideline Summary,” Medical Journal of Australia 219, no. 10 (2023): 485–495, 10.5694/mja2.52136. [DOI] [PubMed] [Google Scholar]
  • 100. Mallick‐Searle T. and Adler J., “Update on Treating Painful Diabetic Peripheral Neuropathy: A Review of Current US Guidelines With a Focus on the Most Recently Approved Management Options,” Journal of Pain Research 17, (2024): 1005–1028, 10.2147/jpr.s442595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 101. NICE . Type 1 Diabetes in Adults: Diagnosis and Management NICE Guideline [NG17], https://www.nice.org.uk/guidance/ng17/chapter/Recommendations#diagnosis‐and‐early‐care‐plan.
  • 102. Zhao J., Zhang Le‐X., Wang Yu‐T., Li Y., and Chen, Md H.‐L., “Genetic Polymorphisms and the Risk of Diabetic Foot: A Systematic Review and Meta‐Analyses,” International Journal of Lower Extremity Wounds 21, no. 4 (2022): 574–587, 10.1177/1534734620977599. [DOI] [PubMed] [Google Scholar]
  • 103. Rolke R., Baron R., Maier C., et al., “Quantitative Sensory Testing in the German Research Network on Neuropathic Pain (DFNS): Standardized Protocol and Reference Values,” Pain 123, no. 3 (2006): 231–243, 10.1016/j.pain.2006.01.041. [DOI] [PubMed] [Google Scholar]
  • 104. Rolke R., Magerl W., Campbell K. A., et al., “Quantitative Sensory Testing: A Comprehensive Protocol for Clinical Trials,” European Journal of Pain 10, no. 1 (2006): 77–88, 10.1016/j.ejpain.2005.02.003. [DOI] [PubMed] [Google Scholar]
  • 105. Dyck P. J., Kratz K. M., Karnes J. L., et al., “The Prevalence by Staged Severity of Various Types of Diabetic Neuropathy, Retinopathy, and Nephropathy in a Population‐Based Cohort,” Neurology 43, no. 4 (1993): 817, 10.1212/wnl.43.4.817. [DOI] [PubMed] [Google Scholar]
  • 106. Rolke R., Baron R., Maier C., et al., “Quantitative Sensory Testing in the German Research Network on Neuropathic Pain (DFNS): Standardized Protocol and Reference Values,” Pain 123, no. 3 (2006): 231–243, 10.1016/j.pain.2006.01.041. [DOI] [PubMed] [Google Scholar]
  • 107. Petropoulos I. N., Ferdousi M., Marshall A., and Alam U., “The Inferior Whorl for Detecting Diabetic Peripheral Neuropathy Using Corneal Confocal Microscopy,” Investigative Ophthalmology & Visual Science 56, no. 4 (2015): 2498–2504, 10.1167/iovs.14-15919. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108. Petropoulos I. N., Green P., Chan A. W. S., Alam U., and Fadavi H., “Corneal Confocal Microscopy Detects Neuropathy in Patients With Type 1 Diabetes Without Retinopathy or Microalbuminuria,” PLoS One 10, no. 4 (2015): e0123517, 10.1371/journal.pone.0123517. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 109. Petropoulos I. N., Ponirakis G., Ferdousi M., Azmi S., and Kalteniece A., “Corneal Confocal Microscopy: A Biomarker for Diabetic Peripheral Neuropathy,” Clinical Therapeutics 43, no. 9 (2021): 1457–1475, 10.1016/j.clinthera.2021.04.003. [DOI] [PubMed] [Google Scholar]
  • 110. Petropoulos I. N., Ponirakis G., Khan A., Almuhannadi H., Gad H., and Malik R. A., “Diagnosing Diabetic Neuropathy: Something Old, Something New,” Diabetes & Metabolism Journal 42, no. 4 (2018): 255, 10.4093/dmj.2018.0056. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 111. Politi C., Ciccacci C., D’Amato C., Novelli G., Borgiani P., and Spallone V., “Recent Advances in Exploring the Genetic Susceptibility to Diabetic Neuropathy,” Diabetes Research and Clinical Practice 120 (2016): 198–208, 10.1016/j.diabres.2016.08.006. [DOI] [PubMed] [Google Scholar]
  • 112. Ginsburg G. S., “A Global Collaborative to Advance Genomic Medicine,” American Journal of Human Genetics 104, no. 3 (2019): 407–409, 10.1016/j.ajhg.2019.02.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113. Dratch L., Azage M., Baldwin A., Johnson K., Paul R. A., and Bardakjian T. M., “Genetic Testing in Adults With Neurologic Disorders: Indications, Approach, and Clinical Impacts,” Journal of Neurology 271, no. 2 (2024): 733–747, 10.1007/s00415-023-12058-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 114. Zeng J., Lu Y., Chu H., et al., “Research Trends and Frontier Hotspots of TRPV1 Based on Bibliometric and Visualization Analyses,” Heliyon 10, no. 2 (2024): e24153, 10.1016/j.heliyon.2024.e24153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 115. Malik R. A., Veves A., Tesfaye S., et al., “Small Fibre Neuropathy: Role in the Diagnosis of Diabetic Sensorimotor Polyneuropathy,” Diabetes‐Metabolism Research and Reviews 27, no. 7 (2011): 678–684, 10.1002/dmrr.1222. [DOI] [PubMed] [Google Scholar]
  • 116. Bril V., “NIS‐LL: The Primary Measurement Scale for Clinical Trial Endpoints in Diabetic Peripheral Neuropathy,” supplement, European Neurology 41, no. S1 (1999): 8–13, 10.1159/000052074. [DOI] [PubMed] [Google Scholar]
  • 117. Bril V., Kojic J., Ngo M., and Clark K., “Comparison of a Neurothesiometer and Vibration in Measuring Vibration Perception Thresholds and Relationship to Nerve Conduction Studies,” Diabetes Care 20, no. 9 (1997): 1360–1362, 10.2337/diacare.20.9.1360. [DOI] [PubMed] [Google Scholar]
  • 118. Bril V., Nyunt M., and Ngo M., “Limits of the Sympathetic Skin Response in Patients With Diabetic Polyneuropathy,” Muscle & Nerve 23, no. 9 (2000): 1427–1430, 10.1002/1097-4598(200009)23:9<1427::aid-mus15>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  • 119. Bril V. and Perkins B. A., “Comparison of Vibration Perception Thresholds Obtained With the Neurothesiometer and the CASE IV and Relationship to Nerve Conduction Studies,” Diabetic Medicine 19, no. 8 (2002): 661–666, 10.1046/j.1464-5491.2002.00759.x. [DOI] [PubMed] [Google Scholar]
  • 120. Ponirakis G., Elhadd T., Al Ozairi E., Brema I., Chinnaiyan S., and Taghadom E., “Prevalence and Risk Factors for Diabetic Peripheral Neuropathy, Neuropathic Pain and Foot Ulceration in the Arabian Gulf Region,” Journal of Diabetes Investigation 13, no. 9 (2022): 1551–1559, 10.1111/jdi.13815. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 121. Ponirakis G., Elhadd T., Chinnaiyan S., Dabbous Z., and Siddiqui M., “Prevalence and Risk Factors for Painful Diabetic Neuropathy in Secondary Healthcare in Qatar,” Journal of Diabetes Investigation 10, no. 6 (2019): 1558–1564, 10.1111/jdi.13037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 122. Ponirakis G., Elhadd T., Chinnaiyan S., and Dabbous Z., “Prevalence and Management of Diabetic Neuropathy in Secondary Care in Qatar,” Diabetes/Metabolism Research and Reviews 36, no. 4 (2020): e3286, 10.1002/dmrr.3286. [DOI] [PubMed] [Google Scholar]
  • 123. Ponirakis G., Elhadd T., Chinnaiyan S., Hamza A. H., and Sheik S., “Prevalence and Risk Factors for Diabetic Neuropathy and Painful Diabetic Neuropathy in Primary and Secondary Healthcare in Qatar,” Journal of Diabetes Investigation 12, no. 4 (2021): 592–600, 10.1111/jdi.13388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 124. Ponirakis G., Fadavi H., Petropoulos I. N., Azmi S., and Ferdousi M., “Automated Quantification of Neuropad Improves its Diagnostic Ability in Patients With Diabetic Neuropathy,” Journal of Diabetes Research 2015, no. 1 (2015): 847854–847857, 10.1155/2015/847854. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 125. Ponirakis G., Odriozola M. N., Odriozola S., Petropoulos I. N., Azmi S., and Fadavi H., “NerveCheck: An Inexpensive Quantitative Sensory Testing Device for Patients With Diabetic Neuropathy,” Diabetes Research and Clinical Practice 113 (2016): 101–107, 10.1016/j.diabres.2015.12.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 126. Ponirakis G., Odriozola M. N., Odriozola S., and Petropoulos I. N., “NerveCheck for the Detection of Sensory Loss and Neuropathic Pain in Diabetes,” Diabetes Technology & Therapeutics 18, no. 12 (2016): 800–805, 10.1089/dia.2016.0279. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 127. Ponirakis G., Petropoulos I. N., Fadavi H., et al., “The Diagnostic Accuracy of Neuropad for Assessing Large and Small Fibre Diabetic Neuropathy,” Diabetic Medicine 31, no. 12 (2014): 1673–1680, 10.1111/dme.12536. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 128. Zochodne D. W., “Diabetic Polyneuropathy: An Update,” Current Opinion in Neurology 21, no. 5 (2008): 527–533, 10.1097/wco.0b013e32830b84cb. [DOI] [PubMed] [Google Scholar]
  • 129. Zochodne D. W., “The Challenges of Diabetic Polyneuropathy: A Brief Update,” Current Opinion in Neurology 32, no. 5 (2019): 666–675, 10.1097/wco.0000000000000723. [DOI] [PubMed] [Google Scholar]
  • 130. Singh A., Bocher O., and Zeggini E., “Insights into the Molecular Underpinning of Type 2 Diabetes Complications,” Human Molecular Genetics 34, no. 6 (2025): 469–480, 10.1093/hmg/ddae203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 131. Miller J. S., Rose M., Roell J., et al., “A Mini Review of Leveraging Biobanking in the Identification of Novel Biomarkers in Neurological Disorders: Insights From a Rapid Single‐Cell Sequencing Pipeline,” Frontiers in Neuroscience 18 (2024): 1473917, 10.3389/fnins.2024.1473917. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 132. Malik R. A., “Is the 10 G Monofilament Fit for Purpose for Diagnosing DPN?,” BMJ Open Diabetes Research & Care 11, no. 6 (2023): e003773, 10.1136/bmjdrc-2023-003773. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 133. Dube S., Hulke S. M., Wakode S. L., et al., “Effectiveness of Semmes Weinstein 10 Gm Monofilament in Diabetic Peripheral Neuropathy Taking Nerve Conduction and Autonomic Function Study as Reference Tests,” Journal of Family Medicine and Primary Care 11, no. 10 (2022): 6204–6208, 10.4103/jfmpc.jfmpc_195_22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 134. Blanchette V., Brousseau‐Foley M., and Cloutier L., “Effect of Contact With Podiatry in a Team Approach Context on Diabetic Foot Ulcer and Lower Extremity Amputation: Systematic Review and Meta‐Analysis,” Journal of Foot and Ankle Research 13, no. 1 (2020): 15, 10.1186/s13047-020-0380-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 135. Meloni M., Giurato L., Monge L., Miranda C., and Scatena A., “Effect of a Multidisciplinary Team Approach in Patients With Diabetic Foot Ulcers on Major Adverse Limb Events (MALEs): Systematic Review and Meta‐Analysis for the Development of the Italian Guidelines for the Treatment of Diabetic Foot Syndrome,” Acta Diabetologica 61, no. 5 (2024): 543–553, 10.1007/s00592-024-02246-9. [DOI] [PubMed] [Google Scholar]
  • 136. Lo Z. J., Tan E., Chandrasekar S., and Ooi D., “Diabetic Foot in Primary and Tertiary (DEFINITE) Care: A Health Services Innovation in Coordination of Diabetic Foot Ulcer (DFU) Care Within a Healthcare Cluster—18‐Month Results From an Observational Population Health Cohort Study,” International Wound Journal 20, no. 5 (2023): 1609–1621, 10.1111/iwj.14016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 137. Zarora R., Immanuel J., Chivese T., MacMillan F., and Simmons D., “Effectiveness of Integrated Diabetes Care Interventions Involving Diabetes Specialists Working in Primary and Community Care Settings: A Systematic Review and Meta‐Analysis,” International Journal of Integrated Care 22, no. 2 (2022): 11, 10.5334/ijic.6025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 138. Shen Q., Li B., Chen H., et al., “Podiatrist Intervention Could Reduce the Incidence of Foot Ulcers in Patients With Diabetes: A Hospital Survey in China,” supplement, Journal of Wound Care 33, no. S4 (2024): S25–S32, 10.12968/jowc.2024.33.sup4.s25. [DOI] [PubMed] [Google Scholar]
  • 139. Bacon D. and Borthwick A. M., “Charismatic Authority in Modern Healthcare: The Case of the ‘Diabetes Specialist Podiatrist’,” Sociology of Health & Illness 35, no. 7 (2013): 1080–1094, 10.1111/1467-9566.12024. [DOI] [PubMed] [Google Scholar]
  • 140. Edwards K., Borthwick A., McCulloch L., and Redmond A., “Evidence for Current Recommendations Concerning the Management of Foot Health for People With Chronic Long‐Term Conditions: A Systematic Review,” Journal of Foot and Ankle Research 10, no. 1 (2017): 51, 10.1186/s13047-017-0232-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 141. Schmidt B. M., Holmes C. M., Najarian K., and Gallagher K., “On Diabetic Foot Ulcer Knowledge Gaps, Innovation, Evaluation, Prediction Markers, and Clinical Needs,” Journal of Diabetes and its Complications 36, no. 11 (2022): 108317, 10.1016/j.jdiacomp.2022.108317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 142. Franks P. W. and Pomares‐Millan H., “Next‐Generation Epidemiology: The Role of High‐Resolution Molecular Phenotyping in Diabetes Research,” Diabetologia 63, no. 12 (2020): 2521–2532, 10.1007/s00125-020-05246-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 143. Haque F., Reaz M. B., Chowdhury M. E. H., et al., “A Nomogram‐Based Diabetic Sensorimotor Polyneuropathy Severity Prediction Using Michigan Neuropathy Screening Instrumentations,” Computers in Biology and Medicine 139 (2021): 11. [DOI] [PubMed] [Google Scholar]
  • 144. Gelaw N. B., Muche A. A., and Alem A. Z., “Development and Validation of Risk Prediction Model for Diabetic Neuropathy Among Diabetes Mellitus Patients at Selected Referral Hospitals, in Amhara Regional State Northwest Ethiopia, 2005–2021,” PLoS One 18, no. 8 (2023): e0276472, 10.1371/journal.pone.0276472. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 145. Wang L., Li J., Lin Y., and Yuan H., “Establishment and External Validation of an Early Warning Model of Diabetic Peripheral Neuropathy Based on Random Forest and Logistic Regression,” BMC Endocrine Disorders 24, no. 1 (2024): 196, 10.1186/s12902-024-01728-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 146. Atmaca A., Ketenci A., Sahin I., and Sengun I. S., “Expert Opinion on Screening, Diagnosis and Management of Diabetic Peripheral Neuropathy: A Multidisciplinary Approach,” Frontiers in Endocrinology 15 (2024): 1380929, 10.3389/fendo.2024.1380929. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 147. Neblett R., Sanabria‐Mazo J. P., Luciano J. V., Mirčić M., and Čolović P., “Is the Central Sensitization Inventory (CSI) Associated With Quantitative Sensory Testing (QST)? A Systematic Review and Meta‐Analysis,” Neuroscience & Biobehavioral Reviews 161 (2024): 105612, 10.1016/j.neubiorev.2024.105612. [DOI] [PubMed] [Google Scholar]
  • 148. Ślęczkowska M., Almomani R., Marchi M., Salvi E., and de Greef B. T. A., “Peripheral Ion Channel Genes Screening in Painful Small Fiber Neuropathy,” International Journal of Molecular Sciences 23, no. 22 (2022): 14095, 10.3390/ijms232214095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 149. Zhang Qi, Yi Na, Liu S., Zheng H., Qiao X., and Xiong Q., “Easier Operation and Similar Power of 10 G Monofilament Test for Screening Diabetic Peripheral Neuropathy,” Journal of International Medical Research 46, no. 8 (2018): 3278–3284, 10.1177/0300060518775244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 150. Young D., Schuerman S., Flynn K., Hartig K., Moss D., and Altenburger B., “Reliability and Responsiveness of an 18 Site, 10‐g Monofilament Examination for Assessment of Protective Foot Sensation,” Journal of Geriatric Physical Therapy 34, no. 2 (2011): 95–98, 10.1519/jpt.0b013e31820aabe5. [DOI] [PubMed] [Google Scholar]
  • 151. Hansson P., Backonja M., and Bouhassira D., “Usefulness and Limitations of Quantitative Sensory Testing: Clinical and Research Application in Neuropathic Pain States,” Pain 129, no. 3 (2007): 256–259, 10.1016/j.pain.2007.03.030. [DOI] [PubMed] [Google Scholar]
  • 152. Wang C.‐S., Pai Y.‐W., Lin C.‐H., Lee I.‐Te, Chen H.‐H., and Chang M.‐H., “Diabetic Peripheral Neuropathy: Age‐Stratified Glycemic Control,” Frontiers in Endocrinology 15 (2024): 1377923, 10.3389/fendo.2024.1377923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 153. Liu M., Gao Y., Chen D.‐W., et al., “Quantitative Vibration Perception Threshold in Assessing Diabetic Polyneuropathy: Should the Cut‐Off Value Be Adjusted for Chinese Individuals With Type 2 Diabetes?,” Journal of Diabetes Investigation 12, no. 9 (2021): 1663–1670, 10.1111/jdi.13515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 154. Madanat A., Sheshah E., Badawy E. L.‐B., Abbas A., and al‐Bakheet A., “Utilizing the Ipswich Touch Test to Simplify Screening Methods for Identifying the Risk of Foot Ulceration Among Diabetics: The Saudi Experience,” Primary Care Diabetes 9, no. 4 (2015): 304–306, 10.1016/j.pcd.2014.10.007. [DOI] [PubMed] [Google Scholar]
  • 155. Basir I. S., Syam Y., Yusuf S., and Sandi S., “Accuracy of Ipswich Touch Test (IpTT) to Detect Small Fiber Neuropathy and Large Fiber Neuropathy as a Risk Factor of Diabetic Foot Ulcers in Public Health Centers,” Enfermería Clínica 30 (2020): 308–312, 10.1016/j.enfcli.2019.07.108. [DOI] [Google Scholar]
  • 156. Hu A., Koh B., and Teo M.‐R., “A Review of the Current Evidence on the Sensitivity and Specificity of the Ipswich Touch Test for the Screening of Loss of Protective Sensation in Patients With Diabetes Mellitus,” Diabetology International 12, no. 2 (2021): 145–150, 10.1007/s13340-020-00451-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 157. Sharma S., Kerry C., Atkins H., and Rayman G., “The Ipswich Touch Test: A Simple and Novel Method to Screen Patients With Diabetes at Home for Increased Risk of Foot Ulceration,” Diabetic Medicine 31, no. 9 (2014): 1100–1103, 10.1111/dme.12450. [DOI] [PubMed] [Google Scholar]
  • 158. Deng P., Shi H., Pan X., Liang H., Wang S., and Wu J., “Worldwide Research Trends on Diabetic Foot Ulcers (2004–2020): Suggestions for Researchers,” Journal of Diabetes Research 2022 (2022): 7991031, 10.1155/2022/7991031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 159. Ziegler D., Burow S., Landgraf R., et al., “Current Practice of Podiatrists in Testing for Diabetic Polyneuropathy and Implementing Foot Care (PROTECT Study Survey 2),” Endocrine Practice 30, no. 9 (2024): 817–821, 10.1016/j.eprac.2024.06.006. [DOI] [PubMed] [Google Scholar]
  • 160. Ahmed Z., “Chapter Four—Precision Medicine With Multi‐Omics Strategies, Deep Phenotyping, and Predictive Analysis,” in Progress in Molecular Biology and Translational Science, ed. Teplow D. B. (Academic Press, 2022), p101–p125. [DOI] [PubMed] [Google Scholar]
  • 161. Son J. H., Xie G., Yuan C., Ena L., Li Z., and Goldstein A., “Deep Phenotyping on Electronic Health Records Facilitates Genetic Diagnosis by Clinical Exomes,” American Journal of Human Genetics 103, no. 1 (2018): 58–73, 10.1016/j.ajhg.2018.05.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 162. Pengelly R. J., “Early Illustrations of the Importance of Systematic Phenotyping,” European Journal of Human Genetics 30, no. 10 (2022): 1102, 10.1038/s41431-022-01165-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 163. Mobasheri A., Kapoor M., Ali S. A., Lang A., and Madry H., “The Future of Deep Phenotyping in Osteoarthritis: How Can High Throughput Omics Technologies Advance Our Understanding of the Cellular and Molecular Taxonomy of the Disease?,” Osteoarthritis and Cartilage Open 3, no. 4 (2021): 100144, 10.1016/j.ocarto.2021.100144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 164. Gannamani R., van der Veen S., van Egmond M., de Koning T. J., and Tijssen M. A. J., “Challenges in Clinicogenetic Correlations: One Phenotype—Many Genes,” Movement Disorders Clinical Practice 8, no. 3 (2021): 311–321, 10.1002/mdc3.13163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 165. van Velzen M., Dahan A., and Niesters M., “Neuropathic Pain: Challenges and Opportunities,” Frontiers in Pain Research 1 (2020): 1, 10.3389/fpain.2020.00001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 166. Ravenscroft J., Liakata M., Clare A., and Duma D., “Measuring Scientific Impact Beyond Academia: An Assessment of Existing Impact Metrics and Proposed Improvements,” PLoS One 12, no. 3 (2017): e0173152, 10.1371/journal.pone.0173152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 167. Tahamtan I. and Bornmann L., “What Do Citation Counts Measure? An Updated Review of Studies on Citations in Scientific Documents Published Between 2006 and 2018,” Scientometrics 121, no. 3 (2019): 1635–1684, 10.1007/s11192-019-03243-4. [DOI] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supporting Information S1

JFA2-18-e70062-s002.docx (15.1KB, docx)

Supporting Information S2

JFA2-18-e70062-s007.docx (17.2KB, docx)

Supporting Information S3

JFA2-18-e70062-s004.docx (17.6KB, docx)

Supporting Information S4

JFA2-18-e70062-s005.docx (612.8KB, docx)

Supporting Information S5

JFA2-18-e70062-s008.docx (48.8KB, docx)

Supporting Information S6

JFA2-18-e70062-s010.docx (3.4MB, docx)

Supporting Information S7

Supporting Information S8

JFA2-18-e70062-s009.docx (18.6KB, docx)

Figure S1

JFA2-18-e70062-s003.docx (1.6MB, docx)

Figure S2

JFA2-18-e70062-s001.docx (103.1KB, docx)

Table S23

JFA2-18-e70062-s006.docx (15.3KB, docx)

Data Availability Statement

The authors have nothing to report.


Articles from Journal of Foot and Ankle Research are provided here courtesy of Wiley

RESOURCES